IHE — iShares U.S. Pharmaceuticals ETF
Data updated: 2026-06-15
IHE — iShares U.S. Pharmaceuticals ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $1.00B AUM · 0.38% expense ratio · 25.2% 1-yr return. From SEC regulatory filings.
IHE Fund Overview
IHE — iShares U.S. Pharmaceuticals ETF is a US ETF managed by iSHARES TRUST, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: iSHARES TRUST
- Category: United States Health Care Equity
- Assets under management: $1.00B
- 1-year return: 25.2%
- Ticker: IHE
- SEC CIK: 0001100663
- SEC series ID: S000009417
- Share class ID: C000025771
IHE Holdings
Top 10 holdings of iShares U.S. Pharmaceuticals ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Johnson & Johnson | 23.03% |
| Eli Lilly And Company | 21.06% |
| Merck & Co., Inc. | 4.74% |
| Pfizer Inc. | 4.71% |
| Royalty Pharma PLC | 4.70% |
| Bristol-Myers Squibb Company | 4.63% |
| Zoetis Inc. | 4.52% |
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | 4.36% |
| Viatris Inc. | 4.35% |
| Elanco Animal Health Incorporated | 3.32% |
IHE Portfolio Allocation
Asset-class allocation of iShares U.S. Pharmaceuticals ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 4.4% |
IHE Performance
Total returns for IHE (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 2.5% |
| 1 year | 25.2% |
| 3 years (annualised) | 15.9% |
| 5 years (annualised) | 9.8% |
IHE Risk Information
Risk metrics for IHE, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 18.2%
IHE Costs and Fees
IHE costs about $38 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.38%
- Gross expense ratio: 0.38%
- Portfolio turnover: 24%
- Brokerage commissions: 0.87 bps of average net assets (SEC N-CEN)
IHE Cashflows
Over the 12 months to 2026-03, iShares U.S. Pharmaceuticals ETF had net inflows of $252.62M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | −$4.63M |
| 2026-02 | $35.81M |
| 2026-01 | $101.55M |
| 2025-12 | $50.48M |
| 2025-11 | $112.34M |
| 2025-10 | $3.75M |
IHE Debt Constituents
No individual debt constituents are reported in iShares U.S. Pharmaceuticals ETF's latest SEC N-PORT filing.
IHE Prospectus and SEC Filings
Official iShares U.S. Pharmaceuticals ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.